RecruitingPhase 4NCT06197295

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity

Sponsor

Mackay Memorial Hospital

Enrollment

200 participants

Start Date

Jun 16, 2022

Study Type

INTERVENTIONAL

Conditions

Urinary Bladder, Overactive Effect of Drug

Summary

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 90 Years

Inclusion Criteria1

Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.

Exclusion Criteria4

Postvoid urine retention before treatment
Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.
Women who were on hormone replacement therapy within 3 months were also excluded from the study

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.